Abstract 5537
Background
The clinical potential of many promising anti-tumor drugs is restricted by their intrinsic physicochemical properties and lack of selectivity towards cancer cells, leading to insufficient drug concentration at the tumor site. To overcome these hurdles, we have developed a new drug delivery system based on polyurea/polyurethane nanocapsules (NCs), which might protect the loaded drug from premature degradation and specifically release it inside cancer cells. Polyurea/polyurethane polymers present amphoteric properties, thus, these NCs are anionic at basic pH and cationic at acid pH. Tumor microenvironment is slightly acidic (6.8-7) in comparison to healthy tissue (7.2-7.4); hence, NCs became cationic in the tumor area, what facilitates their internalization into tumor cells.
Methods
In order to study this novel delivery system, an analog of tambjamine has been loaded in these amphoteric NCs and their selectivity and antitumor properties have been analyzed in vitro comparing two pHs, one acidic (6.8) and another basic (7.5) by proliferation assays, flow cytometry and microscopy. Additionally, the toxicity and efficacy of this delivery approach has been evaluated in an orthotopic lung cancer mouse model.
Results
In vitro results showed higher levels of NCs uptake in tumor cells at pH 6.8, resulting in greater cytotoxic effects compared to those at pH 7.5. Toxicity studies in vivo showed a good tolerability to repeated administrations and furthermore, the encapsulation of the drug reduces its toxicity compared to the free compound, allowing its intravenously administration. Preliminary data show a tendency limiting tumor growth, suggesting that NCs have reached the tumor site and the drug has been released.
Conclusions
Altogether, we have developed a promising new drug delivery system based on polyurea/polyurethane nanocapsules loaded with a tambjamine analog in order to be specifically delivered in cancer cells through reductive conditions, facilitating drug transport to tumor, administration and improving drug safety.
Editorial acknowledgement
Legal entity responsible for the study
Universitat de Barcelona.
Funding
This work was partially supported by a grant from the Spanish government and the EU (PI18/00441).
Disclosure
C. Cuscó: Full / Part-time employment, Not currently employed at Ecopoltech. J. Bonelli: Full / Part-time employment: Ecopoltech. J. Rocas: Leadership role, Officer / Board of Directors: Ecopoltech. All other authors have declared no conflicts of interest.
Resources from the same session
5218 - Elevated driver mutational burden or number of perturbed pathways and poor response to abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
Presenter: Bram De Laere
Session: Poster Display session 3
Resources:
Abstract
2452 - High proportion of multiple KRAS mutations in circulating tumor DNA and tumor tissue of pancreatic ductal adenocarcinoma
Presenter: Min Kyeong Kim
Session: Poster Display session 3
Resources:
Abstract
3328 - Biological difference of tumor mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs. germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
Presenter: Yasuyuki Kawamoto
Session: Poster Display session 3
Resources:
Abstract
3022 - Cell-Free DNA to Detect Focal Versus Non-Focal MET Amplification in Metastatic Colorectal Cancer Patients: Combined Analysis from Japan and the United States
Presenter: Mishima Saori
Session: Poster Display session 3
Resources:
Abstract
2833 - Presence of circulating tumor DNA in surgically resected renal cell carcinoma is associated with advanced disease and poor patient prognosis
Presenter: Andres Correa
Session: Poster Display session 3
Resources:
Abstract
1376 - Combined genomic and epigenomic assessment of cell-free circulating tumor DNA (cfDNA) for cancer diagnosis and recurrence-risk assessment in early-stage lung cancer
Presenter: Junghee Lee
Session: Poster Display session 3
Resources:
Abstract
4050 - DEMo: a prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy.
Presenter: Arsela Prelaj
Session: Poster Display session 3
Resources:
Abstract
4727 - Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single agent pembrolizumab (P)
Presenter: Cindy Yang
Session: Poster Display session 3
Resources:
Abstract
3662 - Dynamic changes in whole-genome cell-free DNA (cfDNA) to identify disease progression prior to imaging in advanced solid tumors
Presenter: Andrew Davis
Session: Poster Display session 3
Resources:
Abstract
3817 - Evaluation of Microsatellite Instability Testing Through cell-free DNA sequencing
Presenter: Shile Zhang
Session: Poster Display session 3
Resources:
Abstract